Nicholas J. Vogelzang, MD

Articles by Nicholas J. Vogelzang, MD

Dr. Vogelzang Discusses First-Line Axitinib in mRCC

May 6th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.

Are We Approaching a Fourth Generation of Therapies for Metastatic Kidney Cancer?

ByNicholas J. Vogelzang, MD,Wolfram Samlowski, MD

April 15th 2008

Drs. Rini and Bukowski do an excellent job of updating and commenting on the rapidly evolving field of therapy for metastatic renal cell carcinoma (RCC).

Latest Updated Articles

Are We Approaching a Fourth Generation of Therapies for Metastatic Kidney Cancer?
Published: April 15th 2008 | Updated:
Dr. Vogelzang Discusses First-Line Axitinib in mRCC
Published: May 6th 2013 | Updated:

Nicholas J. Vogelzang, MD

Articles by Nicholas J. Vogelzang, MD

Dr. Vogelzang Discusses First-Line Axitinib in mRCC

Are We Approaching a Fourth Generation of Therapies for Metastatic Kidney Cancer?

Latest Updated Articles

Trending on CGTlive®

FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More